Exagen (XGN) has disclosed a new risk, in the Regulation category.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Exagen faces potential business risks stemming from ongoing legal proceedings, as outlined in their recent disclosures. These legal challenges could impact the company’s financial stability and operational efficiency. Stakeholders should be aware of the uncertainties associated with litigation outcomes, which may lead to unforeseen expenses or liabilities. The resolution of these proceedings is crucial for Exagen to maintain its market position and investor confidence.
The average XGN stock price target is $10.83, implying 28.93% upside potential.
To learn more about Exagen’s risk factors, click here.